China National Accord Medicines Corporation Ltd. announced unaudited earnings results for the third quarter and nine months ended 30 September 2017. For the quarter, the company reported operating revenue of RMB 10,753,911,112.98; net profit attributable to shareholders of the listed company of RMB 246,977,990.75; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses of RMB 244,923,007.75; basic and diluted earnings per share of RMB 0.577 and weighted average ROE of 2.75%. For the nine months, the company reported operating revenue of RMB 31,278,718,782.55; net profit attributable to shareholders of the listed company of RMB 803,103,308.94; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses of RMB 791,176,397.75; basic and diluted earnings per share of RMB 1.876; net cash flow arising from operating activities of RMB 511,083,437.88 and weighted average ROE of 9.15%.